Myriad Genetics (MYGN) Set to Announce Quarterly Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN) is scheduled to be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Myriad Genetics to post earnings of ($0.11) per share for the quarter. Myriad Genetics has set its FY24 guidance at $0.00-$0.05 EPS and its FY 2024 guidance at 0.000-0.050 EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, February 27th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. Myriad Genetics had a negative net margin of 34.96% and a negative return on equity of 8.03%. The business had revenue of $196.60 million for the quarter, compared to the consensus estimate of $194.80 million. During the same period in the previous year, the company earned ($0.20) earnings per share. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Myriad Genetics Price Performance

Shares of NASDAQ MYGN opened at $19.65 on Monday. The company has a current ratio of 2.01, a quick ratio of 1.87 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average of $20.73 and a 200-day moving average of $19.81. Myriad Genetics has a 12 month low of $13.82 and a 12 month high of $24.21.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group increased their price objective on Myriad Genetics from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Myriad Genetics has an average rating of “Hold” and a consensus price target of $23.17.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.